A model-based pharmacokinetic assessment of drug-drug interaction between tacrolimus and nirmatrelvir/ritonavir in a kidney transplant patient with COVID-19
In conclusion, nirmatrelvir/ritonavir greatly increases tacrolimus concentrations by not only reducing clearance, but also increasing bioavailability. Interactions between nirmatrelvir/ritonavir and low-bioavailability drugs which are substrates for CYP3A and P-glycoprotein, such as tacrolimus, are harmful, and concomitant use of these medicines should be avoided.PMID:37924724 | DOI:10.1016/j.dmpk.2023.100529
Source: Drug Metabolism and Pharmacokinetics - Category: Drugs & Pharmacology Authors: Takeshi Tomida Kotaro Itohara Kazuhiro Yamamoto Takeshi Kimura Kohei Fujita Atsushi Uda Yumi Kitahiro Naoki Yokoyama Yoji Hyodo Tomohiro Omura Ikuko Yano Source Type: research
More News: COVID-19 | Drugs & Pharmacology | Kidney Transplant | Kidney Transplantation | Norvir | Prograf | Tacrolimus | Transplant Surgery | Transplants | Urology & Nephrology